35 completed, 8 unknown, 6 recruiting, 4 active not recruiting. 60 Phase 3, 13 Phase 2.
Follow Isoniazid: new trials by email Literature Review of Isoniazid trials Research Report on Isoniazid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through Active Case Finding (RADIO-TB Trial) Isoniazid (H), Rifampicin (R), Pyrazinamide (Z) - Tuberculosis (TB) | Phase 3 | Recruiting | University College, London | 784 | 2026-10-12 | 2026-10-26 |
| Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB Bedaquiline, Isoniazid, rifapentine, Levofloxacin - Tuberculosis, Latent | Phase 2 / Phase 3 | Recruiting | Johns Hopkins University | 2530 | 2026-05-08 | 2026-10-20 |
| Ultra-Short Regimen for Elderly DS-TB Bedaquiline (B), Sitafloxacin (S), Linezolid (L) - Pulmonary Tuberculosis | Phase 3 | Not yet recruiting | Shenzhen Third People's Hospital | 300 | 2025-07-25 | 2025-07-22 |
| A PAN-USR TB Multi-Center Trial Bedaquiline (B), Sitafloxacin (S), Linezolid (L) - Pulmonary Tuberculosis | Phase 3 | Recruiting | Shenzhen Third People's Hospital | 610 | 2025-06-18 | 2025-12-01 |
| Shortened Regimen for Drug-susceptible TB in Children Isoniazid, Rifampin, Pyrazinamide - Tuberculosis, Tuberculosis, Pulmonary | Phase 3 | Recruiting | Johns Hopkins University | 860 | 2025-01-15 | 2026-11-12 |
| 1HP Versus 3HR in the Treatment of Tuberculosis Infection in Vietnam Isoniazid, Rifapentine, Rifampicin - Tuberculosis Infection | Phase 3 | Withdrawn | Freundeskreis Für Internationale Tuberkulosehilfe e.V | 2024-11-01 | 2026-09-09 | |
| An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM Rifampicin, Azithromycin, Isoniazid - Severe Acute Malnutrition, HIV | Phase 3 | Completed | Queen Mary University of London | 674 | 2024-07-15 | 2026-08-25 |
| Intensified Short Course Regimen for TBM in Adults High dose rifampicin (25mg/kg), Moxifloxacin 400mg, Aspirin 150 mg - Tuberculous Meningitis | Phase 3 | Not yet recruiting | Indian Council of Medical Research | 372 | 2024-03-01 | 2023-12-21 |
| Short-course Regimens for the Treatment of Pulmonary Tuberculosis Rifabutin, Delamanid, Bedaquiline - Tuberculosis, Pulmonary, Tuberculosis Infection | Phase 2 / Phase 3 | Active not recruiting | Centers for Disease Control and Prevention | 288 | 2023-11-21 | 2026-09-21 |
| A Novel Therapy With a 1-Month Ultrashort Regimen to Halt Progression From Latent Infection to Active Tuberculosis Among Close Contacts (The TB-YOUTH Study) isoniazid and rifapentine, Rifampin and Isoniazid - Tuberculosis, Latent Tuberculosis | Phase 3 | Recruiting | Huashan Hospital | 3520 | 2023-09-01 | 2026-07-14 |
| Sitafloxacin-containing Regimens for Shortening Tuberculosis Treatment Sitafloxacin, SMZ/TMP, Rifampin - Tuberculosis, Pulmonary | Phase 3 | Unknown | First Affiliated Hospital of Zhejiang University | 620 | 2022-10-01 | 2022-07-12 |
| Safety of Administering Isoniazid to SLE Patients to Prevent TB Isoniazid/Pyridoxine, Saccharum Lactis - Tuberculosis, Systemic Lupus Erythematosus | Phase 2 / Phase 3 | Unknown | Universitas Padjadjaran | 60 | 2022-08-15 | 2024-10-01 |
| Preventive Treatment Of Latent Tuberculosis Infection In People With Diabetes Mellitus Isoniazid and Rifapentine (INH-RPT), Placebo - Diabetes Mellitus, Tuberculosis | Phase 3 | Unknown | Dr. Nyanda Elias Ntinginya | 3000 | 2022-06-17 | 2023-03-29 |
| Testing New Strategies for Patients Hospitalised With HIV-associated Disseminated Tuberculosis Rifampin, Levofloxacin, Rifampicin, Pyrazinamide, Ethambutol and Isoniazid - Disseminated Tuberculosis, HIV | Phase 3 | Active not recruiting | University of Cape Town | 732 | 2021-08-11 | 2026-01-06 |
| Novel Triple-dose Tuberculosis Retreatment Regimen 6EH³R³Z, 6EHRZ - Multidrug-resistant Tuberculosis, Pulmonary Tuberculosis | Phase 3 | Recruiting | Institute of Tropical Medicine, Belgium | 370 | 2021-03-01 | 2025-04-13 |
| Treating Tuberculosis With the Lipid Lowering Drug Atorvastatin in Nigeria(ATORvastatin in Pulmonary TUBerculosis) Atorvastatin with standard anti tuberculosis drugs, Standard anti tuberculosis drugs only - Tuberculosis, Pulmonary, Tuberculosis | Phase 2 / Phase 3 | Completed | Obafemi Awolowo University Teaching Hospital | 150 | 2021-01-19 | 2023-12-08 |
| Short Course Rifapentine and Isoniazid for the Preventive Treatment for Latent Genital Tuberculosis rifapentine plus isoniazid - Infertility, Female, Recurrent Implantation Failure | Phase 3 | Unknown | Huashan Hospital | 1050 | 2020-09-01 | 2020-08-27 |
| Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3) High-dose rifampicin, Isoniazid, Pyrazinamide - Tuberculosis, Pulmonary | Phase 3 | Not yet recruiting | Seoul National University Hospital | 926 | 2020-09-01 | 2020-07-24 |
| Risk of SDRs Under 3HP and 1HP Regimen for LTBI isoniazid and rifapentine - Latent Tuberculosis Infection | Phase 3 | Completed | National Taiwan University Hospital | 490 | 2019-09-24 | 2023-12-26 |
| Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals Isoniazid/Rifapentine daily (4 weeks) plus pyridoxine (vitamin B6), Isoniazid/Rifapentine 12-weekly plus pyridoxine (vitamin B6) - HIV-infected Participants With Latent TB Infection in High TB Burden Country | Phase 3 | Active not recruiting | The HIV Netherlands Australia Thailand Research Collaboration | 2500 | 2019-08-15 | 2026-09-16 |
Showing 20 of 60. Sign in to see all of them.
Tuberculosis (36) · Tuberculosis, Pulmonary (18) · Latent Tuberculosis (11) · HIV Infections (8) · Tuberculosis, Multidrug-Resistant (7) · Acquired Immunodeficiency Syndrome (5) · AIDS-Related Opportunistic Infections (1) · Child Nutrition Disorders (1) · Diabetes Mellitus (1) · Extensively Drug-Resistant Tuberculosis (1) · Infections (1) · Infertility, Female (1) · Lung Diseases (1) · Lupus Erythematosus, Systemic (1) · Mycobacterium Infections (1)
Centers for Disease Control and Prevention (6) · National Institute of Allergy and Infectious Diseases (NIAID) (6) · National Taiwan University Hospital (4) · Tuberculosis Research Centre, India (4) · University of Cape Town (4) · Global Alliance for TB Drug Development (3) · Huashan Hospital (3) · Johns Hopkins University (2) · McGill University (2) · Shenzhen Third People's Hospital (2) · University College, London (2) · All India Institute of Medical Sciences (1) · Anna Griffiths, MRC (1) · Dr. Nyanda Elias Ntinginya (1) · First Affiliated Hospital of Zhejiang University (1)
South Africa (17) · Uganda (13) · India (11) · United States (9) · Brazil (8) · Canada (6) · China (6) · Kenya (6) · Tanzania (6) · Zimbabwe (6) · Indonesia (5) · Philippines (5) · Taiwan (5) · Thailand (5) · Botswana (4)
Soumya Swaminathan, MD MNAMS (2) · Subodh Katiyar, MD (2) · Susan Swindells, MBBS (2) · A K Jain, MBBS FICA (1) · Alexander Pym, MB BMRCP PhD (1) · Ali Zumla, BSc MBChB MSc PhD (1) · Amina Jindani, MD (1) · Amita Gupta, MD, MHS (1) · Anchalee Avihingsanon, MD, PhD (1) · Andreas Diacon, BM MD (1) · Andrew Nunn, BSc MSc (1) · Andrew Nunn, PhD (1) · Andrey S Borisov, MD, MPH (1) · Angela Crook (1) · Anjula Bhargava, MS (1)
PMID 36808186, PMID 29393655, PMID 31866327, PMID 32539440, PMID 32785709, PMID 36949623, PMID 15844071, PMID 17085459, PMID 17928422, PMID 18230259, PMID 19542476, PMID 19886982, PMID 19965813, PMID 20607114, PMID 20610636, PMID 20627913, PMID 21460373, PMID 21732833, PMID 21732834, PMID 21813327, PMID 22116143, PMID 22150035, PMID 22410137, PMID 22419641, PMID 23251327, PMID 23317958, PMID 23433590, PMID 24099345, PMID 24663014, PMID 24670570, PMID 24903787, PMID 25196020, PMID 25363329, PMID 25404412, PMID 25580725, PMID 25904367, PMID 26038418, PMID 26082504, PMID 26095067, PMID 26104205, PMID 26847437, PMID 26872154, PMID 26929418, PMID 26951571, PMID 27243774, PMID 28087928, PMID 29114781, PMID 29507938, PMID 29653915, PMID 29779774
R01AI048526 (1), U01AI051315 (1), U01AI068632 (1)